TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7915824
Drug: Bromocriptine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (2.5 to 5.0 mg twice daily)
Study: 1102234
Drug: dl‐Fenfluramine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐Fenfluramine hydrochloride (240 mg)
Study: 1102234
Drug: dl‐Fenfluramine hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl‐Fenfluramine hydrochloride (60, 120 mg)
Study: 1102234
Drug: d‐amphetamine sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐amphetamine sulfate (20, 40 mg)
Study: 31977520
Drug: 24 mg
Normalized name: uracil 224 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg dexamethasone
Study: 21319380
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of canales sacralis drop with acupotomy dissolution
Study: 16531710
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with UFT
Study: 11045848
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (10^10 CFU) in enterocoated tablets twice a day for 6 months
Study: 8615097
Drug: Tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 20 mg for 5 days
Study: 8615097
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg for 5 days
Study: 8615097
Drug: Morphine on
Normalized name: Morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine on the day of operation and placebo for 4 days
Study: 4009494
Drug: Intravenous nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine (0.75, 1.5 and 3.0 mg/10‐sec infusion)
Study: 4009494
Drug: Inhaled nicotine
Normalized name: nicotine Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nicotine (0.4, 1.4 and 2.9 mg estimated yield)
Study: 30371791
Drug: BIM23B065 (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM23B065 (1.5 mg)
Study: 30371791
Drug: BIM23B065 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM23B065 (multiple doses)
Study: 30371791
Drug: BIM23B065 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIM23B065 (multiple ascending doses)
Study: 30094984
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6) for 25 min, combined with medication (mifepristone and misoprostol tablets)
Study: 30094984
Drug: Medication (mifepristone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (mifepristone and misoprostol tablets)
Study: 20061873
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure therapy plus cognitive restructuring
Study: 17345556
Drug: Idursulfase (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idursulfase (0.5 mg/kg) administered weekly
Study: 17345556
Drug: Idursulfase (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idursulfase (0.5 mg/kg) administered fortnightly
Study: 17345556
Drug: Idursulfase (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idursulfase (0.5 mg/kg)
Study: 2198233
Drug: Propranolol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol alone (20-80 mg)
Study: 2198233
Drug: Propranolol in
Normalized name: propranolol Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol in combination with dilazep (50 mg three times a day)
Study: 2198233
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of propranolol and dilazep
Study: 346219
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (high-dose methotrexate, adriamycin, and vincristine)
Study: 30829668
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine at 0.25 µg/kg/min
Study: 30829668
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine at 0.375 µg/kg/min
Study: 30829668
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine at 0.5 µg/kg/min
Study: 30829668
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of phenylephrine at 0.625 µg/kg/min
Study: 30063658
Drug: Prophylactic phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic phenylephrine infusion
Study: 21756566
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment for shoulder pain (12-week at-home program)
Study: 15565935
Drug: Budesonide (400microg)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (400microg) administered once daily via Turbuhaler
Study: 15565935
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (400microg) administered twice daily via metered-dose inhaler
Study: 11221554
Drug: Client-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered treatment (CCT)
Study: 11221554
Drug: Client-centered treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-centered treatment (CCT) with additional behavioral exposure treatment
Study: 8512828
Drug: Epirubicin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (30 mg m-2 weekly)
Study: 8512828
Drug: Doxorubicin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (25 mg m-2 weekly)
Study: 30412478
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy plus GPR program
Study: 30412478
Drug: Anti-TNF and
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF and conventional exercise therapy
Study: 26475844
Drug: Ginger (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1,000 mg daily for 10 weeks)
Study: 20485974
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group emphasized on daily oral hygiene.
Study: 16238982
Drug: No cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cardiac resynchronization therapy (Control)
Study: 10085055
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR either alone or in combination
Study: 10085055
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR and CVD 111 combination
Study: 342041
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cephaloridine intraincisionally
Study: 19647066
Drug: Monovalent HPV
Normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent HPV type 16 vaccine
Study: 17268408
Drug: Increased intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased intake of vegetables (400 g/day) and fruit (300 g/day) through a group-based behavioral program for 3 months
Study: 11573627
Drug: Alphadolone (25-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alphadolone (25-500 mg, n = 9)
Study: 9626375
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading dose of carbamazepine 8 mg/kg in suspension form
Study: 9626375
Drug: Oral loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loading dose of carbamazepine 8 mg/kg in tablet form
Study: 9626375
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (tablet and suspension)
Study: 2899237
Drug: Halofantrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine at 10 mg/kg for two doses
Study: 2899237
Drug: Halofantrine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine at 8 mg/kg for three doses
Study: 30130144
Drug: 12-week Iyengar
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week Iyengar Yoga intervention given twice weekly
Study: 30130144
Drug: Twice-weekly 12-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly 12-week program of traditional exercise (e.g., walking, stationary cycling)
Study: 23170990
Drug: Gemigliptin 50
Normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemigliptin 50 mg
Study: 18641545
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg synthetic tetrahydrocannabinol (Marinol)
Study: 16463153
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (MTX) infusion regimens (4-h vs 24-h infusion)
Study: 16463153
Drug: MTX applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX applied as 24-h infusion in all patients with lymphoblastic lymphoma and anaplastic large cell lymphoma
Study: 10897230
Drug: Self-treatment (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment (not consulting a physician)
Study: 8636549
Drug: Treatment delay
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment delay < 1 hour
Study: 8636549
Drug: Treatment delay
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment delay > 90 minutes
Study: 8636549
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to treatment increase
Study: 30773968
Drug: Eltrombopag as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag as monotherapy (Arm A); starting dose 200 mg orally daily
Study: 26490015
Drug: Physician education
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician education and audit/feedback on antibiotic prescribing quantity and quality
Study: 24606090
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PVI once daily
Study: 24606090
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PVI once daily
Study: 24606090
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PVI once daily
Study: 24606090
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PVI twice daily
Study: 24606090
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PVI twice daily
Study: 24606090
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PIO via im injection once daily
Study: 24606090
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg PIO via im injection once daily
Study: 24606090
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg PIO via im injection once daily
Study: 22313739
Drug: Ginger (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (1.5 g/d in 3 divided doses every 8 hours) plus standard antiemetic regimen (granisetron plus dexamethasone)
Study: 17684881
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus intravenous hydrocortisone (200 mg first, then 100 mg TID for 48 hours)
Study: 17684881
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (complete bed rest, hydration, acetaminophen and pethidine)
Study: 10666547
Drug: Intramuscular capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular capsaicin 100 microg/1 ml
Study: 10666547
Drug: Intramuscular capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular capsaicin 100 microg/20 microl
Study: 10666547
Drug: Intradermal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal capsaicin 100 microg/20 microl
Study: 10666547
Drug: Intramuscular capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular capsaicin 1 ml
Study: 10666547
Drug: Intramuscular capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular capsaicin 20 microl
Study: 1730811
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate injections (3 mg/kg.week, im)
Study: 29771789
Drug: Raltegravir 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 1200 mg once daily (QD)
Study: 29771789
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily (BID)
Study: 25239225
Drug: Trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.3 mg/m(2) once every 3 weeks (1/3 treatment arm)
Study: 25239225
Drug: Trabectedin 0.58
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 0.58 mg/m(2) every week for 3 of 4 weeks (3/4 treatment arm)
Study: 15838067
Drug: Metformin, 850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, 850 mg twice daily
Study: 10713806
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily gentamicin (4 mg/kg)
Study: 10713806
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily gentamicin (2.5 mg/kg)
Study: 29438649
Drug: Cannabidiol as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol as an anticonvulsant drug
Study: 21943315
Drug: Telepsychiatry-based culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Study: 23227679
Drug: Conventional acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional acupuncture therapy (4 weeks, 3-5 treatments per week)
Study: 15124981
Drug: R-roscovitine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-roscovitine (50, 100, 200, 400, or 800 mg)
Study: 15124981
Drug: R-roscovitine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-roscovitine (50, 100, 200, 400, or 800 mg) after breakfast
Study: 11773168
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (cisplatin-based) followed by radical surgery (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy)
Study: 9839764
Drug: Theophylline in
Normalized name: theophylline Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline in combination with donepezil (5 mg, once daily for 10 days)
Study: 2572652
Drug: Ranitidine, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 300 mg
Study: 998148
Drug: Atropine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.1 mg/10 kg intravenously 2 min before induction)
Study: 31331572
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 4 weeks
Study: 26008138
Drug: Intravenous doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxycycline 200, 100 and 100mg
Study: 26008138
Drug: Intravenous doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous doxycycline 100, 50 and 50mg
Study: 24094495
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of growth hormone (3mg/24h) for 60 hours
Study: 21724796
Drug: RENEW program
Approvals — FDA: no, EMA: no, PMDA: no
Description: RENEW program (meal replacements twice daily, intensive instruction in nutrition and meal preparation, exercise, and goal setting for three months)
Study: 17072091
Drug: Atropine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.01 mg kg(‐1))
Study: 8953321
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for bulimia nervosa
Study: 1411629
Drug: Carboplatin 60
Normalized name: CARBOPLATIN 600MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin 60 mg/m2 with 67.2 Gy radiation
Study: 1411629
Drug: Simultaneous chemoradiotherapy
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous chemoradiotherapy (various carboplatin doses with radiation)
Study: 1411629
Drug: Sequential chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential chemoradiotherapy (carboplatin/5-fluorouracil followed by conventional radiotherapy)
Study: 31087542
Drug: TCZ‐SC 162
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCZ‐SC 162 mg q2w
Study: 27872513
Drug: Lactoferrin (LF)
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (LF) administration 4 hours before amniocentesis
Study: 27872513
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no LF treatment)
Study: 22809012
Drug: Pazufloxacin mesilate
Normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin mesilate 300 mg
Study: 22809012
Drug: Pazufloxacin mesilate
Normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin mesilate 500 mg
Study: 22809012
Drug: Pazufloxacin mesilate
Normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin mesilate 600 mg
Study: 22809012
Drug: Pazufloxacin mesilate
Normalized name: pazufloxacin
DrugBank: Pazufloxacin (DB11774)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazufloxacin mesilate 1,000 mg
Study: 17583378
Drug: Risk factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk factors for lacking medications
Study: 15821120
Drug: Gemcitabine 1200
Normalized name: gemcitabine 1200 MG in 120 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1200 mg/m² on days 1, 8, and 15 of a 28-day cycle
Study: 15821120
Drug: Epirubicin 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 35 mg/m² on days 1, 8, and 15 of a 28-day cycle
Study: 31436705
Drug: Small-quantity lipid-based
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-quantity lipid-based nutrient supplement provided to pregnant and lactating mothers and their children
Study: 28798089
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n=156)
Study: 23924586
Drug: DRV/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 800/100 mg once daily (OD) monotherapy
Study: 23924586
Drug: DRV/r 800/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DRV/r 800/100 mg OD plus 2 nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 20625394
Drug: Solar simulated
Normalized name: Bos taurus solar plexus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solar simulated radiation (SSR) at doses of 2 and 4 J/cm²
Study: 11189100
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (Cisplatin 100 mg/m2 on day 1 and fluorouracil 1000 mg/m2/day for 5 days, every 21 days) followed by loco-regional treatment.
Study: 11189100
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy followed by loco-regional treatment.
Study: 11189100
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (Cisplatin and fluorouracil) followed by loco-regional treatment.
Study: 7504379
Drug: Killed Mycobacterium
Normalized name: Heat Killed Mycobacterium W Immunomodulator
DrugBank: Mycobacterium w. Vaccine (DB15798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed Mycobacterium leprae vaccine
Study: 2990332
Drug: Paper tissues
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paper tissues treated with a combination of citric acid, malic acid, and sodium lauryl sulfate
Study: 30400977
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (urapidil, nicardipine, labetalol)
Study: 18476430
Drug: Shuxuetong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong Injection (SXTI) high dose (8 mL/d)
Study: 18476430
Drug: Shuxuetong Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong Injection (SXTI) low dose (6 mL/d)
Study: 15546907
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg zoledronic acid iv, administered as three monthly doses
Study: 10530684
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 3600 mg per day)
Study: 3047380
Drug: Sulindac 400
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 400 mg daily
Study: 3047380
Drug: Sulindac 600
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulindac 600 mg daily
Study: 26032168
Drug: Quinine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (80 mg)
Study: 26032168
Drug: Oxycodone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (30 mg)
Study: 26032168
Drug: Quinine and
Normalized name: quinine and urea HCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine and Oxycodone (80 mg and 30 mg respectively)
Study: 23530757
Drug: Intramuscular magnesium
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular magnesium sulphate regimen
Study: 23530757
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulphate regimen
Study: 22059194
Drug: Tapentadol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol IR (50 mg or 100 mg every 4 to 6 hours as needed)